Datopotamab Deruxtecan for Lung Cancer Examined

Patients with EGFR-mutated lung cancer may see different response rates and side effect profiles with this new therapy.

Updated on Oct. 21, 2026 in Cancer

Microscopic view of cellular structures in cool blue and teal tones, representing precision medical research. — Recent clinical data on datopotamab deruxtecan highlights both potential efficacy and the necessity for managing adverse side effects in lung cancer patients. AI Illustration. Upload story photo >

Live Poll

Do you trust that new medical treatments are worth the potential risks of severe side effects?

Recent findings presented on September 14, 2026, detail the efficacy and side effect profile of the antibody-drug conjugate datopotamab deruxtecan for patients with EGFR-mutated non-small cell lung cancer. Experts noted that while the treatment shows clinical activity, managing adverse events remains a primary focus for oncologists.

Why it matters

Selecting a treatment plan for lung cancer requires balancing tumor response against the potential for significant side effects like stomatitis and ocular issues. Because these therapies have distinct tolerability profiles, clinicians and patients must weigh these risks carefully when deciding on the next steps in their care.

In a pooled analysis of 117 patients with EGFR-mutated non-small cell lung cancer, datopotamab deruxtecan yielded an objective response rate of 43%. While the agent showed clinical activity, investigators noted that 60% of patients experienced stomatitis and 32% reported ocular surface events.

The players

OncLive

A digital platform providing oncology news and information to health professionals.

The details

Datopotamab deruxtecan is a TROP2-directed antibody-drug conjugate that delivers chemotherapy directly to cells expressing the TROP2 protein. To manage side effects like inflammation of the mouth lining, clinicians use dexamethasone mouthwash and provide patients with frozen oral mouthpieces during infusions. Because of the frequency of ocular side effects, consistent access to ophthalmology services is required to monitor and mitigate vision-related complications during treatment.

September 14, 2026: Thoracic oncologists reviewed data at the OncLive Scientific Interchange and Workshop.
October 21, 2026: Findings were published following the expert meeting.

Health Landscape

The development of TROP2-directed therapies follows the complex results of the EVOKE-03/KEYNOTE-D46 trial, which highlighted the difficulty of reaching statistical significance in advanced lung cancer. Research is currently evolving to determine where these drugs sit relative to established standards of care like osimertinib.

Patients currently exploring treatment options for EGFR-mutated lung cancer should discuss the specific side effect profiles of various therapies with their oncology team. It is worth asking your doctor about proactive management strategies, such as the use of dexamethasone mouthwash to limit potential treatment-related discomfort.

The takeaway

While datopotamab deruxtecan demonstrates clinical activity, it requires careful management of side effects to ensure patient quality of life. If you are undergoing treatment, ensure your care plan includes a strategy for monitoring ocular health and mitigating oral inflammation through consultation with your physician.